New Hope for Chronic Migraine: Botox SPG Injection Trial

Research Summary

This study, published in F1000Research, explores a new treatment strategy for those with treatment-resistant chronic migraine using onabotulinumtoxinA injections targeting the sphenopalatine ganglion (SPG). The MiBlock trial is a rigorous, multi-centre, quadruple-blinded, placebo-controlled study involving 170 participants from Norwegian university hospitals. It aims to assess the efficacy and safety of a single-session, bilateral, navigation-guided injection of either onabotulinumtoxinA or a placebo under local anesthesia. The primary focus is on changes in the frequency of moderate to severe headache days 5-8 weeks post-injection, tracked via daily headache eDiary entries. This trial may illuminate the feasibility of SPG injections in various headache disorders.

Study Details

📄 Title: OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial.

👥 Research Team: Wergeland T et al.

📚 Published In: F1000Res

📅 Publication Date: 2025

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.